Patents by Inventor Hwan Jung Lim
Hwan Jung Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11767297Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: September 7, 2022Date of Patent: September 26, 2023Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Publication number: 20230039679Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: September 7, 2022Publication date: February 9, 2023Inventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Patent number: 11485711Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: January 31, 2019Date of Patent: November 1, 2022Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Patent number: 11464770Abstract: Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 27, 2017Date of Patent: October 11, 2022Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
-
Patent number: 11447469Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: GrantFiled: January 31, 2019Date of Patent: September 20, 2022Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
-
Publication number: 20220160747Abstract: The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of cancer comprising a novel azolopyrimidine heterocyclic compound as an active ingredient, and the pharmaceutical composition for the prophylaxis or treatment of cancer of the present invention can be used as a small molecular immunotherapy anticancer agent which modulates an adenosine pathway by comprising the azolopyrimidine heterocyclic compound.Type: ApplicationFiled: March 20, 2020Publication date: May 26, 2022Inventors: Seong Jun PARK, Chang Hoon LEE, Hwan Jung LIM
-
Publication number: 20220017491Abstract: The present invention relates to a compound which inhibits the binding of Yes associated protein (YAP) and transcriptional enhancer associate domain (TEAD), a prodrug of same, a hydrate of same, a solvate of same or a pharmaceutically acceptable salt of same, and a composition comprising same as an active ingredient, the compound according to the present invention being able to be applied as an inhibitor which can directly inhibit YAP-TEAD binding in the Hippo pathway which plays a crucial role in the occurrence of cancer.Type: ApplicationFiled: November 8, 2019Publication date: January 20, 2022Inventors: Hwan Jung LIM, Seong Jun PARK, Chang Hoon LEE, Kyoung Tai NO, Jiwon CHOI, Hei-Cheul JEUNG, You-keun SHIN, Jong Wan KIM, Xuemei JIN
-
Publication number: 20210315879Abstract: Provided is a method for treating or preventing cancer, containing, as an active ingredient, a compound having a specific chemical structure and an activity of inhibiting the formation of a c-Myc/Max/DNA complex, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 27, 2017Publication date: October 14, 2021Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
-
Publication number: 20210047277Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Publication number: 20210047300Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Sung Youn CHANG, Hyuk LEE, Ki Young KIM, Bum Tae KIM, Sung Soo KIM, Seong Hwan KIM, Hwan Jung LIM, Jung Nyoung HEO, Sang Joon SHIN, Sang Youn PARK
-
Patent number: 10227306Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.Type: GrantFiled: March 1, 2018Date of Patent: March 12, 2019Assignees: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
-
Patent number: 10179785Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: GrantFiled: July 10, 2015Date of Patent: January 15, 2019Assignee: ST PHARM CO., LTD.Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
-
Publication number: 20180186744Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 1, 2018Publication date: July 5, 2018Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
-
Patent number: 9951021Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.Type: GrantFiled: July 28, 2017Date of Patent: April 24, 2018Assignees: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae Jeong, Hwan Jung Lim, Seong Jun Park, Ho Kyung Seo, Kyung Ohk Ahn, Sang Jin Lee, Eun Sook Lee
-
Patent number: 9914737Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: GrantFiled: July 10, 2015Date of Patent: March 13, 2018Assignee: ST PHARM CO., LTD.Inventors: Jung Nyoung Heo, Hwan Jung Lim, Kwang Rok Kim, Kyung Jin Kim, Uk Il Kim, Hyung Tae Bang, Ji Hye Yoon
-
Publication number: 20180029988Abstract: Disclosed are novel compounds of specific chemical structures having inhibitory activity on c-Myc/Max/DNA complex formation or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: July 28, 2017Publication date: February 1, 2018Applicants: NATIONAL CANCER CENTER, KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Kyung Chae JEONG, Hwan Jung LIM, Seong Jun PARK, Ho Kyung SEO, Kyung Ohk AHN, Sang Jin LEE, Eun Sook LEE
-
Publication number: 20170166572Abstract: The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: ApplicationFiled: July 10, 2015Publication date: June 15, 2017Inventors: Jung Nyoung HEO, Hwan Jung LIM, Kwang Rok KIM, Kyung Jin KIM, Uk Il KIM, Hyung Tae BANG, Ji Hye YOON
-
Publication number: 20170145016Abstract: The present invention relates to a novel triazolopyrimidinone or triazolopyridinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.Type: ApplicationFiled: July 10, 2015Publication date: May 25, 2017Inventors: Jung Nyoung HEO, Hwan Jung LIM, Kwang Rok KIM, Kyung Jin KIM, Uk Il KIM, Hyung Tae BANG, Ji Hye YOON
-
Patent number: 9018233Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.Type: GrantFiled: May 7, 2013Date of Patent: April 28, 2015Assignees: Kyung Nong Corporation, Korea Research Institute of Chemical TechnologyInventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim
-
Publication number: 20150094342Abstract: The invention relates to diaminoaryl derivatives substituted by carbamate, salts thereof and a pesticidal composition containing the same, which exhibit superior pest control effects against various insect pests of insect species, in particular against moths such as the diamondback moth or Spodoptera litura.Type: ApplicationFiled: May 7, 2013Publication date: April 2, 2015Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, KYUNG NONG CORPORATIONInventors: Sung Youn Chang, Jung Nyoung Heo, Hyuk Lee, Hwan Jung Lim, Bum Tae Kim, Joo Kyung Kim, Jong-Kwan Kim